Press "Enter" to skip to content

Tag: medical treatments

Common diabetes drug lowers SARS-CoV-2 levels, clinical trial finds

Today, researchers from the University of Minnesota published evidence that the common diabetes drug metformin decreases the amount of SARS-CoV-2 in the body and helps reduce the risk of rebound symptoms if given early in the course of non-severe illness.

The study, published in Clinical Infectious Diseases, suggests metformin may also help prevent long COVID.

The researchers tested metformin against a placebo in 999 adults infected with COVID-19. More than 50% of the study enrollees were vaccinated, and treatment took place when the Omicron variant was the most dominant strain in the United States.

Comments closed

Long COVID still has no cure — so these patients are turning to research

When Lisa McCorkell got COVID-19 in March 2020, her symptoms were mild. Her physicians told her to isolate from others and that she would recover in a few weeks. But the weeks stretched into months and McCorkell, who was working on a master’s degree in public policy at the University of California, Berkeley, started having debilitating and bewildering symptoms: fatigue, dizziness and shortness of breath. Previously an avid runner, McCorkell found her heart racing from simple efforts.

She struggled to find an explanation, and soon realized that her physicians didn’t know any more about her condition than she did. To complicate matters, the limited availability of high-quality testing for the coronavirus SARS-CoV-2 in the early days of the pandemic left many of her doctors wondering whether her symptoms were really due to COVID-19 at all. “I didn’t have health-care providers that took me seriously,” McCorkell says. “That largely pushed me out of the health-care system.”

McCorkell turned instead to those who were experiencing the same puzzling symptoms and frustrations, joining a support group for people with what would eventually be called long COVID. As they compared notes, McCorkell and a handful of others — many of whom had research experience — realized that the information they were sharing might be helpful not only for those with long COVID, but also for those looking to study the condition. So, they founded a non-profit organization, called the Patient-Led Research Collaborative (PLRC), to design, provide advice on and even fund basic and clinical research into long COVID and other chronic illnesses.

Comments closed

13 Things To Know About Paxlovid, the Latest COVID-19 Pill

Note: Information in this article was accurate at the time of original publication. Because information about COVID-19 changes rapidly, we encourage you to visit the websites of the Centers for Disease Control & Prevention (CDC), World Health Organization (WHO), and your state and local government for the latest information.

Paxlovid, an oral antiviral pill that can be taken at home, is the go-to treatment for COVID-19. If you are at high risk for severe disease from COVID, and you take it within the first five days of experiencing symptoms, it will lower your risk of getting so sick that you need to be hospitalized.

Comments closed

Four years after COVID’s arrival, Austin’s ‘long haulers’ still search for answers

They do an activity that would normally not be tiring — it can be a pretty small mental or physical activity, [like] folding laundry, reading an email — and it just knocks them out and makes all their symptoms worse.

Comments closed

Four years later, long COVID continues to upend lives in Quebec

Sylvie Gagnon has been struggling with the symptoms of long COVID since early 2023, when she caught the virus for a fourth time since the outset of the pandemic.

A business development manager, Gagnon has been off work ever since. Needing help with daily tasks, she’s had to move in with her son and daughter-in-law.

On the few days she manages to leave the house in Vaudreuil-Dorion, she wears sunglasses and earmuffs — the condition has played havoc with her senses, leaving her hypersensitive to light and noise. Her pressure spikes without warning. Any exercise causes extreme fatigue.

Comments closed

Long COVID Doesn’t Always Look Like You Think It Does

In the spring of 2023, after her third case of COVID-19, Jennifer Robertson started to feel strange. Her heart raced all day long and she could barely sleep at night. She had dizzy spells. She felt pins and needles in her arm, she says, a “buzzing feeling” in her foot, and pain in her legs and lymph nodes. She broke out in a rash. She smelled “phantom” cigarette smoke, even when none was in the air.

Robertson, 48, had a feeling COVID-19 might have somehow been the trigger. She knew about Long COVID, the name for chronic symptoms following an infection, because her 11-year-old son has it. But “he didn’t have anything like this,” she says. “His set of symptoms are totally different,” involving spiking fevers and vocal and motor tics. Her own experience was so different from her son’s, it was hard to believe the same condition could be to blame. “I just thought, ‘It’s really coincidental that I never got well, and now I’m getting worse,’” she says.

Comments closed

Millions of Americans suffer from long COVID. Why do treatments remain out of reach?

More than a year after catching COVID-19, Sawyer Blatz still can’t practice his weekly rituals: running for miles in San Francisco’s Golden Gate Park or biking around his adopted hometown.

In many ways, the pandemic isn’t over for the 27-year-old and millions of other Americans. It may never be.

They have long COVID, a condition characterized by any combination of 200 different lingering symptoms, some of which, like loss of taste and smell are familiar from initial infections and some totally alien, like the utter exhaustion that makes it impossible for Blatz to walk much more than a block.

Comments closed

New antibody treatment for RSV in infants highly effective in reducing hospitalisations

A new antibody treatment could reduce by 80 per cent the numbers of babies and young children admitted to hospital with respiratory syncytial virus (RSV), a “groundbreaking” study has found.

Published in the New England Journal of Medicine on Thursday, the study involved 8,058 healthy babies aged up to 12 months from the UK, France and Germany, who were approaching their first RSV season. Half were randomly assigned to receive the antibody nirsevimab by injection, while 4,021 babies received standard care.

Of the babies who received the treatment, only 11 (0.3 per cent) were hospitalised, in comparison with the 60 babies (1.5 per cent) who were hospitalised after receiving just the standard care.

Comments closed

Canada enters 5th year of COVID-19. Are we falling short in treatment?

As Canada enters its fifth year navigating COVID-19, some experts and advocates are worried treatment options for the virus remain disappointingly inadequate.

Despite significant strides in understanding the virus, Jennifer Hulme, a 42-year-old emergency physician at the University Health Network in Toronto, says many Canadians suffering from long-term COVID-19 are left without many options.

She is one of them.

Comments closed

Early Paxlovid for COVID-19 halved death, hospitalization in new study

Starting the antiviral drug nirmatrelvir-ritonavir (Paxlovid) 0 or 1 day after COVID-19 symptom onset halved 28-day all-cause death and hospitalization rates compared with waiting 2 or more days, University of Hong Kong researchers report in Nature Communications.

Comments closed

Many Canadians have had long COVID for almost 4 years. Researchers say there’s hope

Four years ago, Sonja Mally was a busy tattoo artist with a photographic memory and penchant for long hikes.

Now, the 38-year-old Toronto woman considers it a good day if she can do a small drawing, muster the energy to walk around the block or “perform very basic tasks.”

“It’s a hard thing to have to explain to people why maybe one day you might be doing fine and the next day you can’t find the words to complete a sentence,” Mally said.

Comments closed

Le mystère entourant la COVID longue limite les capacités de traitements

Four years after the first cases of what was later called COVID-19, infections continue to spread and lead to new cases of long COVID. However,…

Comments closed

Ivermectin warnings, a new COVID-19 antiviral, a changing threshold for care: These are the WHO’s updated treatment guidelines

The World Health Organization (WHO) has updated its guidelines for the treatment of COVID-19 patients, including categories of hospitalization risk to help doctors tailor treatment, and recommendations surrounding a new antiviral designed specifically to tackle the disease.

Comments closed

Pfizer more than doubles price of lifesaving Covid-19 medication Paxlovid as US transitions out of pandemic phase

The price of the lifesaving Covid-19 antiviral medication Paxlovid will more than double as the United States transitions out of the emergency phase of the pandemic, drugmaker Pfizer said Wednesday.

Comments closed

Smell loss from COVID fades quickly with help of new pill

New clinical-trial data suggest that an antiviral pill called ensitrelvir shortens the duration of two unpleasant symptoms of COVID-19: loss of smell and taste. The medication is among the first to alleviate these effects and, unlike other COVID-19 treatments, is not reserved only for people at high risk of severe illness.

Comments closed

Long COVID: The hunt for causes and cures

Hannah Davis misses her old self. Like so many people around the world, she has seen her life upended by long COVID, which has made many once-routine activities impossible. The 32-year-old has stopped working at her job in the field of machine learning and generative models. It’s too cognitively taxing; the lights from display monitors are disorienting. Merely standing up from a sitting position causes her heart rate to shoot to 170 beats per minute, the equivalent of doing a good jog.

Comments closed

Un médicament québécois démontre son efficacité contre la COVID-19

A cocktail of antibodies developed by the Quebec company Immune Biosolutions has proven its effectiveness in relieving respiratory symptoms caused by COVID-19 in the acute phase of the disease.

Comments closed